Detalhe da pesquisa
1.
Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers.
Blood
; 137(3): 374-386, 2021 01 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-32663292
2.
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.
N Engl J Med
; 379(26): 2517-2528, 2018 12 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-30501481
3.
The Effect of Added Peanut Butter on the Glycemic Response to a High-Glycemic Index Meal: A Pilot Study.
J Am Coll Nutr
; 38(4): 351-357, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30395790
4.
Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103.
Blood
; 128(21): 2510-2516, 2016 11 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-27697771
5.
Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma.
Blood
; 128(12): 1562-6, 2016 09 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-27432875
6.
Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma.
Blood
; 125(8): 1236-43, 2015 Feb 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-25533035
7.
Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
Biol Blood Marrow Transplant
; 22(8): 1391-1396, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-27164062
8.
Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable.
Br J Haematol
; 175(4): 631-640, 2016 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-27469075
9.
Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation.
Blood
; 120(3): 560-8, 2012 Jul 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-22510871
10.
Myeloablative Vs. Non-Myeloablative Consolidation for Primary Central Nervous System Lymphoma: Results of Alliance 51101.
Blood Adv
; 2024 Apr 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38598710
11.
Prevention of nausea and vomiting associated with stem cell transplant: results of a prospective, randomized trial of aprepitant used with highly emetogenic preparative regimens.
Biol Blood Marrow Transplant
; 19(1): 49-55.e1, 2013 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-22863840
12.
Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma: A Multi-institutional Phase 2 Investigator-Initiated Nonrandomized Clinical Trial.
JAMA Oncol
; 9(5): 683-691, 2023 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36928527
13.
A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome.
Cancer
; 118(8): 2138-47, 2012 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21887679
14.
Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202.
Leukemia
; 35(10): 2854-2861, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34274940
15.
Burkitt Lymphoma International Prognostic Index.
J Clin Oncol
; 39(10): 1129-1138, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33502927
16.
HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis.
Blood Adv
; 5(14): 2852-2862, 2021 07 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-34283175
17.
Busulfan, melphalan, and bortezomib compared to melphalan as a high dose regimen for autologous hematopoietic stem cell transplantation in multiple myeloma: long term follow up of a novel high dose regimen.
Leuk Lymphoma
; 61(14): 3484-3492, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32865474
18.
Evaluation of Risk Factors for Clostridium difficile Infection in Hematopoietic Stem Cell Transplant Recipients.
Pharmacotherapy
; 37(4): 420-428, 2017 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-28226419
19.
Novel treatment of blastic plasmacytoid dendritic cell neoplasm: A case report.
Medicine (Baltimore)
; 96(51): e9452, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-29390581
20.
Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
Lancet Haematol
; 4(4): e176-e182, 2017 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-28314699